DiscoverBiotech MattersEp.3 What We're Watching at ASCO 2024
Ep.3 What We're Watching at ASCO 2024

Ep.3 What We're Watching at ASCO 2024

Update: 2024-05-30
Share

Description

As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics:

  1. What are the unmet needs in 1L therapy?
  2. The KRAS G12C mutation landscape
Comments 
In Channel
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Ep.3 What We're Watching at ASCO 2024

Ep.3 What We're Watching at ASCO 2024

Bluestar BioAdvisors